Sarah A. Reda

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d2a5b100-504e-11ef-931e-8373c6b518fb.jpg

First Name

Sarah

Last Name

Reda

NPI

1003304510

Faculty ID

17794

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

186405

Visit Type ID

2499

Is Open Scheduling

On

Sriram Machineni

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c68653a0-bec9-11ee-aa99-759018b444d6.jpg

First Name

Sriram

Last Name

Machineni

NPI

1750350666

Faculty ID

17510

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni obtained his medical degree from the All India Institute of Medical Sciences in New Delhi, followed by a residency in internal medicine at the State University of New York at &nbsp;Buffalo. He served as chief resident and primary care teaching physician at Buffalo General Hospital. He subsequently completed a clinical and research fellowship in obesity medicine and metabolism at Massachusetts General Hospital/ Harvard Medical School and stayed on as an instructor. Dr. Machineni studied energy balance and body fat regulation in animal models allowing the interpretation of clinical research findings and phenotypes in the context of physiology.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni moved to the University of North Carolina at Chapel Hill (UNC) to start a clinical obesity program for treatment, education, and pharmaceutical clinical obesity trials. During his term at UNC, he helped create an obesity primary care network in central North Carolina. He was recruited to Montefiore Medical Center to develop a new medical obesity program.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">The Fleischer Institute Medical Weight Center at Montefiore Einstein, founded by Dr. Machineni, is designed to support clinical, educational, and research endeavors in the field of obesity medicine. The program leverages individual variations in response to treatments and uses multiple modalities for weight reduction to treat the comorbidities of obesity and improve quality of life. Special programs are available for individuals who need to lose weight to quality for medical and surgical procedures. The Medical Weight Center works closely with the Montefiore bariatric surgery program to offer a broad spectrum of treatment modalities.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">Dr. Machineni has clinical expertise in the m</span><span style="font-family: Calibri, sans-serif; font-size: 12pt;">ultidisciplinary management of obesity, anti-obesity medications, and post-bariatric medical complications, including nutritional deficiencies, hypoglycemia, weight regain, malabsorption, and diarrhea. He</span><span style="font-family: Calibri, sans-serif;">&nbsp;is among a handful of physicians in the New York area with Castle Connolly Top Doctors designation in obesity medicine.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p>1: Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H,Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; <strong>SURMOUNT-2 investigators</strong>.Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi:10.1016/S0140-6736(23)01200-X. Epub ahead of print. PMID: 37385275.</p>
<p>2: Pagidipati NJ, Mulder H, Chiswell K, Lampron Z, Jones WS, <strong>Machineni S</strong>,Waitman LR, Mongraw-Chaffin M, Waterman F, Kumar N, Ramasamy A, Smolarz G,Peterson ED, O'Brien E. Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity. PrevMed. 2023 May;170:107496. doi:10.1016/j.ypmed.2023.107496. Epub 2023 Mar 29.PMID: 36997096.</p>
<p>3: Ro SJ, Lackey AR, Aymes SE, McCauley JL, Davis TC, Wang R, Stanley W, Ratner SP, <strong>Machineni S</strong>, Fiscus LC. Impact of a Community-Based Weight Management Program in a North Carolina Health Care System. Fam Med. 2023 Mar;55(3):189-194.doi: 10.22454/FamMed.2023.603918. Epub 2023 Jan 31. PMID: 36888674.</p>
<p>4: Aronne LJ, Bramblette S, Ingelfinger JR, Jastreboff AM, <strong>Machineni S,</strong> Massie N, Rosen CJ. When Weight Impacts Health. N Engl J Med. 2023 Jan 12;388(2):e2. doi: 10.1056/NEJMp2215794. PMID: 36630621.</p>
<p>5: Aronne LJ, Bramblette S, Huett-Garcia A, Ingelfinger JR, Jastreboff AM, <strong>Machineni S</strong>, Massie N, Rosen CJ. Weight and Health - Pathophysiology and&nbsp;Therapies. N Engl J Med. 2022 Dec 15;387(24):e62. doi: 10.1056/NEJMp2214423. PMID: 36516089.</p>
<p>6: le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, <strong>Machineni S</strong>, Dunn J, Chigutsa FB, Ahmad NN, Bunck MC. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2023 Jan;31(1):96-110. doi: 10.1002/oby.23612. Epub 2022 Dec 7. PMID: 36478180; PMCID: PMC10107501.</p>
<p>7: Bionic Pancreas Research Group; Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K,Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB,Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, <strong>Machineni S</strong>, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172. doi: 10.1056/NEJMoa2205225. PMID: 36170500; PMCID: PMC10028490.</p>
<p>8: Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, <strong>Machineni S</strong>, Varbo A,Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism andGlycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg AmongParticipants With Prediabetes in the STEP Program. Diabetes Care. 2022 Oct1;45(10):2396-2405. doi: 10.2337/dc21-1785. PMID: 35724304; PMCID: PMC9862484.</p>
<p>9: Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A,Zhang S, Liu B, Bunck MC, Stefanski A; <strong>SURMOUNT-1 Investigators</strong>. TirzepatideOnce Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.</p>
<p>10: Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, Valcarce C;<strong>SimpliciT1 research group</strong>. The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. Diabetes Care. 2021 Apr;44(4):960-968. doi:10.2337/dc20-2684. Epub 2021 Feb 23. PMID:33622669; PMCID: PMC7985421.</p>
<p>11: Melanie Davies, Louise F&aelig;rch, Ole K Jeppesen, Arash Pakseresht, Sue D Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A Wadden, Ildiko Lingvay; <strong>STEP 2 Study Group</strong>.&nbsp; Semaglutide 2&middot;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. PMID: 33667417.</p>
<p>12: Rosman L, Armbruster T, Kyazimzade S, Tugaoen Z, Mazzella AJ, Deyo Z, Walker J, <strong>Machineni S,</strong> Gehi A. Effect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19. Pacing Clin Electrophysiol. 2021 Mar;44(3):451-461. doi: 10.1111/pace.14188. Epub 2021 Feb 17. PMID: 33565642; PMCID: PMC8014277.</p>
<p>13: Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; <strong>STEP 3 Investigators.</strong> Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Feb 24. PMID: 33625476; PMCID: PMC7905697.</p>
<p>14: Jensen SM, Thompson RE, <strong>Machineni S,</strong> Overby DW, Farrell TM. Refractory Hypocalcemia Following Stomach Intestinal Pylorus-Sparing Bariatric Surgery and Thyroidectomy: Successful Management With Creation of a Proximal Roux-en-Y Gastric Bypass. Am Surg. 2021 Apr;87(4):576-580. doi: 10.1177/0003134820952427. Epub 2020 Oct 30. PMID: 33125276.</p>
<p>&nbsp;</p>
<p>15: Kushner RF, Batsis JA, Butsch WS, Davis N, Golden A, Halperin F, Kidambi S, <strong>Machineni S,</strong> Novick M, Port A, Rubino DM, Saunders KH, Shapiro Manning L, Soleymani T, Kahan S. Weight History in Clinical Practice: The State of the Science and Future Directions. Obesity (Silver Spring). 2020 Jan;28(1):9-17. doi: 10.1002/oby.22642. PMID: 31858735.</p>
<p>16: Kushner RF, Butsch WS, Kahan S, <strong>Machineni S,</strong> Cook S, Aronne LJ. Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested? Teach Learn Med. 2017 Apr-Jun;29(2):123-128. doi:10.1080/10401334.2016.1250641. Epub 2016 Dec 29. PMID: 28033472.</p>
<p>17: Carmody JS, Ahmad NN, <strong>Machineni S,</strong> Lajoie S, Kaplan LM. Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice. Endocrinology. 2015 Sep;156(9):3183-91. doi: 10.1210/en.2015-1226. Epub 2015 Jun 11. PMID: 26066076; PMCID: PMC4541621.</p>
<p>18: Liou AP, Paziuk M, Luevano JM Jr, <strong>Machineni S,</strong> Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013 Mar 27;5(178):178ra41. doi:10.1126/scitranslmed.3005687. PMID: 23536013; PMCID: PMC3652229.</p>
<p>19: Bose M, Teixeira J, Olivan B, Bawa B, Arias S, <strong>Machineni S,</strong> Pi-Sunyer FX, Scherer PE, Laferr&egrave;re B. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010 Mar;2(1):47-55. doi: 10.1111/j.1753-0407.2009.00064.x. PMID: 20676394; PMCID: PMC2910618.</p>
<p>20: Bose M, <strong>Machineni S,</strong> Oliv&aacute;n B, Teixeira J, McGinty JJ, Bawa B, Koshy N, Colarusso A, Laferr&egrave;re B. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010 Jun;18(6):1085-91. doi: 10.1038/oby.2009.473. Epub 2010 Jan 7.PMID: 20057364; PMCID: PMC2877144.</p>

EMR ID

179058

Is Open Scheduling

Off

Shiu M. Young

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Shiu

Last Name

Young

NPI

1467742726

Faculty ID

14110

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5826

Is Open Scheduling

Off

Beatrice Y. Wong

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b4012680-c3c5-11eb-9ea2-7374238588d1.jpg

First Name

Beatrice

Last Name

Wong

NPI

1033656541

Faculty ID

16257

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

95560

Visit Type ID

2499

Is Open Scheduling

On

Diana S. Wolfe

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/2dbd2620-c4a9-11eb-9a84-87080e863cf8.jpg

First Name

Diana

Last Name

Wolfe

NPI

1972755445

Faculty ID

13455

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Diana S Wolfe, MD MPH is an Associate Professor in the Department of Obstetrics &amp; Gynecology and Women&rsquo;s Health, Division of Maternal Fetal Medicine. &nbsp;She is Associate Program Director of the Maternal Fetal Medicine Fellowship Program. &nbsp;</p>
<p>She established the MFM Cardiology Joint Program in 2015&nbsp;in response to the rising contribution of cardiovascular conditions to pregnancy related morbidity and mortality.&nbsp;&nbsp;The aim was to establish a multidisciplinary program to optimize the care of high-risk pregnant patients with known or suspected cardiac disease, as there is a real potential for communication gaps when patients are seen separately in contrast with parallel visits by different specialists.&nbsp;&nbsp;Patients are at all stages of their reproductive lives including preconception, pregnancy and postpartum.&nbsp;&nbsp;She works closely with the department of Cardiology both in the outpatient and inpatient setting to establish delivery plans and continued care postpartum.&nbsp;&nbsp;</p>
<p>&nbsp;</p>
<p>In addition,&nbsp;Dr. Wolfe has worked in global health,&nbsp;her most recent work in Africa was in Butare (Huye), Rwanda, serving as MFM subspecialist in the Human Resources for Health (HRH) program, directed by the Clinton Health Access Initiative (CHAI) and the Ministry of Health (MOH) of Rwanda.&nbsp; Dr. Wolfe was the first MFM subspecialist from Einstein to commence HRH at CHUB, Butare, Rwanda.&nbsp;&nbsp;Her interest began&nbsp;locally when she volunteered as a bilingual pregnancy counselor in Escondido, California.&nbsp; She then started working in Africa in 1998 where she served as a Peace Corps Volunteer in Mali, West Africa.&nbsp; She was part of the national Maternal and Child Health Program.&nbsp; She worked as health educator in a remote village, Karangasso, located in the Sikasso region, with a birth assistant to develop health education for 7 local villages on subjects such as infant nutrition, prenatal care, family planning, and developing community health committees for each village. &nbsp;She also initiated a birth assistant training program with the head nurse of the nearest local health center that included training subjects such as management of postpartum hemorrhage, contraception, and first steps in obstetric emergencies.&nbsp;&nbsp;During medical school, Dr. Wolfe worked on &ldquo;the Assessment of the Knowledge of Women&rsquo;s Health,&rdquo; a project that initiated with the Bedoin community of Israel.&nbsp; She implemented the same pre and post-training test to the 7 Malian villages where she served in the Peace Corps as well as to several villages in the Peruvian Amazon.&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Wolfe&rsquo;s clinical focus is on maternal and fetal medicine (MFM).

Elsevier Profile

PubMed.gov URL

Selected Publications

<ol>
<li>Wolfe DS, Hameed AB, Taub CC, Zaidi AN, Bortnick AE.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/30278179">Addressing maternal mortality: the pregnant cardiac patient.</a>&nbsp;&nbsp;Am J Obstet Gynecol. 2019 Feb;220(2):167.e1-167.e8. doi: 10.1016/j.ajog.2018.09.035. Epub 2018 Sep 29.</li>
<li>Sahasrabudhe N, Teigen N, Wolfe DS, Taub C.&nbsp;&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/29581907">Pregnancy after Prosthetic Aortic Valve Replacement: How Do We Monitor Prosthetic Valvular Function during Pregnancy?</a>Case Rep Obstet Gynecol. 2018 Jan 17;2018:4935957. doi: 10.1155/2018/4935957. eCollection 2018.</li>
<li>Kim SY, Wolfe DS, Taub CC.&nbsp;&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/29063738">Cardiovascular outcomes of pregnancy in Marfan's syndrome patients: A literature review.</a>&nbsp;&nbsp;Congenit Heart Dis. 2018 Mar;13(2):203-209. doi: 10.1111/chd.12546. Epub 2017 Oct 23. Review.</li>
<li>Wolfe DS, Williams SF, Ross MG, Beall MH, Apuzzio JJ.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/23943702">Does preeclampsia predict the risk of late postpartum eclampsia?</a>&nbsp;&nbsp;AJP Rep. 2013 May;3(1):13-6. doi: 10.1055/s-0032-1329127. Epub 2013 Jan 25.</li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Wolfe%20D%5BAuthor%5D&amp;cau… D</a>1,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Gong%20M%5BAuthor%5D&amp;caut… M</a>,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Han%20G%5BAuthor%5D&amp;cauth… G</a>,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Magee%20TR%5BAuthor%5D&amp;ca… TR</a>,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Ross%20MG%5BAuthor%5D&amp;cau… MG</a>,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Desai%20M%5BAuthor%5D&amp;cau… M</a>.Nutrient&nbsp;sensor mediated&nbsp;programmed&nbsp;nonalcoholic&nbsp;fatty&nbsp;liver&nbsp;disease&nbsp;in&nbsp;low&nbsp;birthweight offspring.&nbsp;&nbsp;<a title="American journal of obstetrics and gynecology." href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Nutrient+sensor-mediated+prog… J Obstet Gynecol.</a>&nbsp;2012 Oct;207(4):308.e1-6. doi: 10.1016/j.ajog.2012.07.033. Epub 2012 Jul 31.</li>
</ol>

EMR ID

5620

Biography

<p>Diana S. Wolfe, MD, MPH, FACOG is Attending Physician at Montefiore and Associate Professor of Obstetrics and Gynecology and Women&rsquo;s Health at our Albert Einstein College of Medicine. Dr. Wolfe&rsquo;s clinical focus is on maternal and fetal medicine (MFM). In 2015, she established the MFM-Cardiology Joint Program at Montefiore&mdash;a multidisciplinary program to reduce morbidity and prevent mortality in expecting mothers with cardiovascular disease by optimizing the care of high-risk pregnant patients.</p><p>From 1988 to 1993, Dr. Wolfe pursued her Bachelor of Science in biology through the University of California San Diego, participating in the Education Abroad Program with Universita di Bologna, Italy from 1990 through 1991. In 1996 she began studies at University of California, Berkeley focusing on maternal child health, earning her Master of Public Health in 1998. After two years serving in the health extension of the Child Health Survival Program with the Peace Corps in Mali, Dr. Wolfe pursued her Doctor of Medicine at Ben Gurion University, Israel, receiving her degree in 2004.</p><p>Building on her clinical focus, Dr. Wolfe&rsquo;s research investigates cardio-obstetrics, preconception health, maternal morbidity and contraception in high risk women. She has published her research in several reviewed journals, book chapters and review articles.</p><p>Dr. Wolfe is board certified and is a member of the American College of Obstetrics and Gynecology and the Society for Maternal Fetal Medicine. She is active in global health, most recently working in Butare (Huye), Rwanda, serving as MFM subspecialist in the Human Resources for Health program, directed by the Clinton Health Access Initiative and the Ministry of Health of Rwanda.</p>

Is Open Scheduling

Off

Samson Wiseman

https://assets.montefioreeinstein.org/profiles/images/physphoto/Wiseman_Samson_MD_420x504.jpg

First Name

Samson

Last Name

Wiseman

NPI

1588761316

Faculty ID

10181

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4748

Is Open Scheduling

Off

Yaron Tomer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e3b1f380-8c61-11ed-9474-c3e3b839843d.jpg

First Name

Yaron

Last Name

Tomer

NPI

1982662334

Faculty ID

14884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Yaron Tomer is the Marilyn and Stanley M. Katz Dean at Albert Einstein College of Medicine and Chief Academic Officer at Montefiore Medicine.</p>
<p>He received his M.D. degree magna cum laude from the Sackler School of Medicine of Tel Aviv University and trained in Internal Medicine at Sheba Medical Center, Israel, and in Endocrinology at the Icahn School of Medicine at Mount Sinai in New York. Prior to joining Montefiore Einstein in March 2016, he was Chief of the Division of Endocrinology, Diabetes, and Bone Disease at Mount Sinai.</p>
<p>Dr. Tomer has served on the editorial boards of <em>Endocrinology </em>and <em>The Journal of Clinical Endocrinology and Metabolism</em>, among others. He is a member of the American Society for Clinical Investigation and a Fellow of the American College of Physicians. Dr. Tomer is the recipient of several prestigious awards, including the American Thyroid Association&rsquo;s Sidney H. Ingbar Distinguished Lectureship Award, as well as its Van Meter Award.</p>
<h3>Research</h3>
<p>Dr. Tomer&rsquo;s research program focuses on the immunogenetic, epigenetic, and environmental mechanisms underlying thyroid autoimmunity, and type 1 diabetes, and on targeting these mechanisms in order to develop novel therapies. His group made several discoveries including identifying new genes and mechanisms underlying the strong association between type 1 diabetes and autoimmune thyroiditis; demonstrating that CD40 and thyroglobulin are major susceptibility genes for thyroid autoimmunity; identifying a unique amino acid variant in the peptide binding pocket of HLA-DR that is key for the development of thyroid autoimmunity; dissecting the epigenetic mechanisms by which polymorphisms in the thyroglobulin and TSHR genes interact with environmental agents (e.g. viruses) to trigger thyroid autoimmunity; and identifying a novel small molecule that can block antigen presentation in autoimmune thyroiditis.</p>
<h3>Current Projects</h3>
<ol role="list">
<li><strong>Genetic and epigenetic studies in thyroid autoimmunity</strong><br />The Tomer lab mapped several susceptibility genes for autoimmune thyroid diseases (AITD) including CD40, thyroglobulin, and TSHR. Recent data suggest that variants in regulatory regions of some of these genes interact epigenetically with environmental factors (e.g., viral infections) to trigger disease. Current studies are using epigenomic screening, including whole genome methylation studies and ChiP-seq analyses to study these genetic-epigenetic interactions.</li>
<li><strong>Epigenetic studies in type 1 diabetes</strong><br />Similar studies are utilizing epigenomic screening to analyze epigenetic interactions between known type 1 diabetes susceptibility genes and interferon alpha, a key cytokine secreted during viral infections.</li>
<li><strong>Translational studies in autoimmune thyroiditis (AITD) and type 1 diabetes</strong><br />The Tomer lab discovered that the presence of arginine at position beta-74 of the peptide binding pocket of HLA-DR is critical for the development of AITD. This discovery led to a translational project aimed at blocking thyroid antigen presentation to T-cells by the arginine beta-74 HLA-DR peptide binding pocket as a potential therapy for AITD. Recently, the Tomer lab identified a small molecule, Cepharanthine, that can block antigen presentation and suppress AITD in mouse models. Similar studies are performed in type 1 diabetes where the aim is to block the HLA-DQ8 peptide binding pocket from presenting insulin peptides to T-cells as a novel strategy to treat autoimmune diabetes.</li>
<li><strong>Genetic and functional analyses of autoimmune polyglandular syndrome (APS) type 3</strong><br />The co-occurrence of type 1 diabetes and autoimmune thyroiditis in the same individual is considered a variant of the APS type 3 syndrome. The Tomer lab discovered several new susceptibility genes for APS3. The lab is now analyzing the mechanisms by which these genes predispose to disease.</li>
<li><strong>The role of viruses in triggering autoimmune thyroiditis and type 1 diabetes</strong><br />Certain infections, such as hepatitis C, are associated with autoimmune thyroiditis and diabetes. Current studies are aimed at dissecting the mechanisms by which interferon alpha, the primary cytokine secreted during viral infections, can trigger autoimmune thyroiditis and diabetes in genetically susceptible individuals.</li>
</ol>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol role="list">
<li>Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, Davies TF, Ban Y, Jacobson EM, Concepcion ES, Li CW, <span class="underline">Tomer Y</span>. Molecular amino acid signatures in the MHC class II peptide binding pocket predispose to autoimmune thyroiditis in humans and in mice. Proc Natl Acad Sci USA 2008; 105: 14034-14039.</li>
<li>Jacobson EM, Yang H, Menconi F, Wang R, Osman R, Skrabanek L, Li CW, Fadlalla M, Gandhi A, Chaturvedi V, Smith EP, Schwemberger S, Osterburg A, Babcock GF, <span class="underline">Tomer Y</span>. Employing a recombinant HLA-DR3 expression system to dissect MHC II-thyroglobulin peptide dynamism: A genetic, biochemical, and reverse immunological perspective. J Biol Chem 2009; 284: 34231-34243.</li>
<li>Villano MJ, Huber AK, Greenberg DA, Golden BK, Concepcion E, <span class="underline">Tomer Y</span>. Autoimmune thyroiditis and diabetes: Dissecting the joint genetic susceptibility in a large cohort of multiplex families. J Clin Endocrinol Metab 2009; 94: 1458-1466.</li>
<li>Menconi F, Osman R, Monti MC, Greenberg DA, Concepcion ES, <strong>Tomer Y</strong>. Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis. Proc Natl Acad Sci USA 2010; 107: 16899-16903.</li>
<li>Menconi F, Huber A, Osman R, Concepcion E, Jacobson EM, Stefan M, David, CS, <span class="underline">Tomer Y</span>. Tg.2098 is a major human thyroglobulin T-cell epitope. J Autoimmun 2010; 35: 45-51.</li>
<li>Stefan M, Jacobson EM, Huber AK, Greenberg DA, Li CW, Skrabanek L, Concepcion E, Fadlalla M, Ho K, <span class="underline">Tomer Y</span>. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J Biol Chem 2011; 286: 31168-31179.</li>
<li>Huber AK, Finkelman FD, Li CW, Concepcion E, Smith E, Jacobson E, Latif R, Keddache M, Zhang W, <span class="underline">Tomer Y</span>. Genetically driven target tissue overexpression of CD40: A novel mechanism in autoimmune disease. J Immunol 2012; 189: 3043-3053.</li>
<li>Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB 3rd, Owen R, Zhang W, <span class="underline">Tomer Y</span>. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci USA 2014; 111: 12562-12567.</li>
<li><span class="underline">Tomer Y</span>, Dolan LM, Kahaly G, Divers J, D&rsquo;Agostino Jr. RB, Imperatore G, Dabelea D, Marcovina S, Black MH, Pihoker C, Hasham A, Hammerstad SS, Greenberg DA, Lotay V, Zhang W, Monti MC, Matheis N. Genome wide identification of new genes and pathways in patients with autoimmune thyroiditis and type 1 diabetes. J Autoimmun 2015; 60: 32-39.</li>
<li>Li CW, Menconi F, Osman R, Mezei M, Jacobson EM, Concepcion E, David CS, Kastrinsky DB, Ohlmeyer M, <strong>Tomer Y</strong>. Identifying a small molecule blocking antigen presentation in autoimmune thyroiditis. J Biol Chem 2016; 291: 4079-4090.</li>
<li>Li CW, Osman R, Menconi F, Concepcion ES, <span class="underline">Tomer Y</span>. Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes. J Autoimmun 2017; 76: 1-9.</li>
<li>Faustino LC, Lombardi A, Madrigal-Matute J, Owen RP, Libutti SK, <span class="underline">Tomer Y</span>. Interferon alpha triggers autoimmune thyroid diseases via lysosomal-dependent degradation of thyroglobulin. J Clin Endocrinol Metab 2018; 103: 3678-3687.</li>
<li>Stefan-Lifshitz, M, Karakose E, Cui L, Ettela A, Yi Z, Zhang W, <span class="underline">Tomer Y</span>. Epigenetic modulation of &beta;-cells by interferon-&alpha; via PNPT1-miR26a-TET2 triggers autoimmune diabetes. JCI Insight 2019; 4: e126663.</li>
<li>Li CW, Osman R, Menconi F, Concepcion E, <span class="underline">Tomer Y</span>. Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves&rsquo; disease. J Autoimmun 2020; 108: 102402.</li>
<li>Lombardi, A, Concepcion E, Hou H, Arib H, Mezei M, Osman R, <span class="underline">Tomer Y</span>. Retro-inverso D-peptides as a novel targeted immunotherapy for type 1 diabetes. J Autoimmune 2020; 115: 102543.</li>
<li>Li CW, Sachidanandam R, Jayaprakash A, Yi Z, Zhang W, Stefan-Lifshitz M, Concepcion E, <span class="underline">Tomer Y</span>. Identification of new rare variants associated with familial autoimmune thyroid diseases by deep sequencing of linked loci. J Clin Endocrinol Metab 2021; 12: 691781.</li>
<li>Ye J, Stefan-Lifshitz M, <span class="underline">Tomer Y</span>. Genetic and environmental factors regulate the type 1 diabetes gene CTSH via differential DNA methylation. J Biol Chem 2021; 296: 100774.</li>
<li>Li CW, Osman R, Menconi F, Faustino LC, Kim K, Clarke OB, Hou H, <span class="underline">Tomer Y</span>. Cepharanthine blocks presentation of thyroid and islet peptides in a novel humanized autoimmune diabetes and thyroiditis mouse model. Front Immunol 2021; 12: 796552.</li>
</ol>

EMR ID

81697

Is Open Scheduling

Off

Peter L. Tenore

https://assets.montefioreeinstein.org/profiles/images/9816-tenore.jpg

First Name

Peter

Last Name

Tenore

NPI

1316063027

Faculty ID

9816

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

Dr. Tenore is a Medical Director in the Division of Substance Abuse and is a wekk known figure in this field, having published in several journals and providing education in substance abuse to local and state agencies. He is an advisor to the New York State Ofice of Alcoholism and Substance Abuse Services and the federal Center for Substance Abuse Treatment. He is certified in Internal Medicine and by examination in Addiction Medicine and a New York State HIV Provider. His particular interests are management of cocaine and other addictions as well as providing hepatitis C and HIV treatment in the methadone clinic setting.

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

DINO-VAMP: A Helpful Acronym in Determining Optimal Methadone Dosing and Brief review of Dosing Literature, Journal of Maintenance in the Addictions, Vol.2(4).

Guidance On Optimal Methadone Dosing, Addiction Treatment Forum, Vol.12 (2).

Methadone:A Medical Model in "Innovations in Substance Abuse Treatment and Policy," Yale University Center for Interdisciplinary Research, Yale Publicatinos, New Haven, CT.

Three Oral Formulations of Methadone: A Clinical and Pharmacodynamic Comparison, Journal of Substance Abuse Treatment, Vol. 17(3), Gourevitch, Hartell, Tenore, et al.

EMR ID

3901

Is Open Scheduling

Off

Vafa Tabatabaie

https://assets.montefioreeinstein.org/profiles/images/Tabatabaie_Vafa_MD_2x.jpg

First Name

Vafa

Last Name

Tabatabaie

NPI

1861789976

Faculty ID

13732

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Vafa Tabatabaie received her medical degree from Shahid Beheshti Medical University in Tehran, Iran. After several years of research on thyroid cancer in Toronto, Canada, she came to Montefiore in 2007, initially as a clinical observer and then as a researcher in the Division of Endocrinology under the direction of Drs. Norman Fleischer and Martin Surks. She graduated from the Internal Medicine Residency Program in 2011, during which her enthusiasm and teaching skills were recognized with the Award for Outstanding House Officer in Internal Medicine. She then completed her Endocrinology Fellowship in 2013 and joined the Einstein Montefiore Division of Endocrinology faculty later that year.</p>
<p>Dr. Tabatabaie is the Clinical Director for Division of Endocrinology.&nbsp;She is also the Director of Fracture Liaison Services, a multi-disciplinary team of Endocrinologist, Geriatricians and Orthopedic Surgeons focused on secondary prevention of osteoporotic fractures. &nbsp;Dr Tabatabaie is one of the founding members of Transgender Interest Group at Montefiore/Einstein. Her clinical research interests include endocrine issues in the elderly, especially metabolic bone disease and osteoporosis, as well as thyroid cancer. She has contributed to the field of endocrinology by writing journal articles, presenting posters at national endocrine meetings, and mentoring medical students, residents and fellows. In recognition of her contributions to medical education, she was accepted into Leo M Davidoff Society in 2019. She also received Department of Medicine's Humanism Award in 2018.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort</strong></p>
<p>Cancers,&nbsp;<span style="caret-color: #5b616b; color: #5b616b; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">2021 Mar 23;13(6):1464</span></p>
<p>&nbsp;</p>
<p><strong>Are We Responding Effectively to Bone Mineral Density Loss and Fracture Risk in People with Epilepsy?</strong></p>
<p>Epilepsia Open, 2020 Apr 14;5(2): 240-247</p>
<p>&nbsp;</p>
<p><strong>Changes in Bone Mineral Density During 5 Years of Adjuvant Treatment in Premenopausal Breast Cancer Patients</strong></p>
<p>Breast Cancer Research and Treatment, 2020 Feb 19</p>
<p>&nbsp;</p>
<p><strong>Treatment of Diabetic Ketoacidosis and The Weekend Effect at an Urban Tertiary-Care Center</strong></p>
<p>Endocrine Practice,&nbsp;<span style="caret-color: #5b616b; color: #5b616b; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">2020 Jun 2;26(6):634-641</span></p>
<p>&nbsp;</p>
<p><strong>Thyroid Storm Presenting as Psychosis</strong></p>
<p>Journal of Investigative Medicine High Impact Case Reports, May 2018</p>
<p>&nbsp;</p>
<p><strong>Medical Optimization of Lumbar Fusion in the Osteoporotic Patient</strong></p>
<p>Archives of Osteoporosis, 2018 March 14: 13 (1): 26</p>
<p>&nbsp;</p>
<p><strong>Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels</strong></p>
<p>Journal Of Clinical Endocrinology and Metabolism. 2016 Aug; 101 (8): 3096-104</p>
<p>&nbsp;</p>
<p><strong>Effects of Testosterone Treatment in Older Men</strong></p>
<p>New England Journal of Medicine, 2016 Feb 18: 374 (7): 611-24</p>
<p>&nbsp;</p>
<p><strong>Recruitment and Screening for the Testosterone Trials</strong></p>
<p>The Journals of Gerontology, 2015 Sep, 70(9): 1105-11</p>
<p>&nbsp;</p>
<p><strong>Association of Sex Hormones with Sexual Function, Vitality, and Physical Function of Symptomatic Older Men with Low Testosterone Levels at Baseline in the Testosterone Trials</strong></p>
<p>Journal of Clinical Endocrinology and Metabolism, 2015 Mar, 100(3):1146-55</p>
<p>&nbsp;</p>
<p><strong>Exceptional Longevity is Associated with Decreased Reproduction</strong></p>
<p>Aging, 2011 Dec, 3(12):1202-5</p>
<p>&nbsp;</p>
<p><strong>Influence of Age and Primary Tumor Size on the Risk for Residual/Recurrent Well-Differentiated Thyroid Carcinoma</strong></p>
<p>Head and Neck, 2009 Jun; 31(6):782-8</p>
<p>&nbsp;</p>
<p><strong>Post-Challenge Hyperglycemia in Older Adults is Associated with Increased Cardiovascular Risk Profile</strong></p>
<p>Journal of Clinical Endocrinology and Metabolism, 2009 May, 94(5):1595-601</p>
<p>&nbsp;</p>
<p><strong>Prognostic Value of Postsurgical Stimulated Thyroglobulin Levels after Initial Radioactive Iodine Therapy in Well-Differentiated Thyroid Carcinoma</strong></p>
<p>Head and Neck, 2008 Jun; 30(6):693-700</p>

EMR ID

5083

Biography

<p>Dr. Vafa Tabatabaie received her medical degree from Shahid Beheshti University of Medical Sciences in Tehran, Iran. After several years of research on thyroid cancer in Toronto, Canada, she came to Montefiore in 2007 as a researcher in the Division of Endocrinology under the direction of Drs. Norman Fleischer and Martin Surks. She graduated from the Internal Medicine Residency Program in 2011, during which her enthusiasm and teaching skills were recognized with the Award for Outstanding House Officer in Internal Medicine, and she completed the Endocrinology Fellowship Program in 2013. She joined the Einstein Montefiore Division of Endocrinology faculty later that year.</p><p>Dr. Tabatabaie is Director of the Fracture Liaison Service at Montefiore Medical Center. Her clinical research interests include endocrine issues in the elderly, especially metabolic bone disease and osteoporosis, as well as thyroid cancer.</p>

Visit Type ID

2499

Is Open Scheduling

On

Martin I. Surks

https://assets.montefioreeinstein.org/profiles/images/physphoto/Surks_Martin_I_MD_2835.jpg

First Name

Martin

Last Name

Surks

NPI

1891885794

Faculty ID

4372

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Current Activities:</strong>&nbsp;</p>
<ul>
<li>Program Director, Division of Endocrinology and Metabolism, Albert Einstein College of Medicine</li>
<li>Director of the Endocrinology Clinic, Montefiore Medical Center</li>
<li>Consultant in thyroid disease and general endocrinology</li>
<li>Research Mentor</li>
</ul>
<p>&nbsp;<strong>Clinical Practice:</strong></p>
<p>Dr. Surks restricts his consultative practice to disorders of the thyroid gland, and to other disorders of general endocrinology such as diseases of the pituitary, parathyroid glands, gonads, adrenal glands, and to metabolic bone disease.</p>
<p>&nbsp;<strong>Research Interests:</strong></p>
<p>Historical Summary:&nbsp;Major contributions from thyroid research at Montefiore Medical Center began nearly 100 years ago with findings of Dr. David Marine, Chairman of Pathology, that deficiency of iodine was associated with development of goiter and iodine deficiency diseases that affected hundreds of millions of people around the world His studies initiated iodine supplementation to salt in the US, and elimination of this major health problem. A Medical Physics laboratory, the progenitor of Nuclear Medicine Departments, was established in 1945 and was widely known for the earliest studies of radioactive iodine use to treat hyperthyroidism and thyroid cancer. From 1960 to 1976, Dr. Jack Oppenheimer published widely on thyroid hormone measurements and metabolism, discovered the nuclear receptor for thyroid hormone and studied its effects on different gene products</p>
<p>Most of Dr. Surks&rsquo; research has focused on thyroid physiology, pathophysiology and diseases. For the last five years, he has studied subclinical thyroid diseases, and the characterization of the reference range for serum TSH in human beings.&nbsp;</p>

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Surks is a thyroid disease expert with 40 years of experience in basic and clinical research, education and patient care. In addition to thyroid disorders, his clinical practice focuses on conditions of the pituitary, parathyroid and adrenal glands and on metabolic bone disease. His recent research has involved subclinical thyroid diseases and determining a reference range for TSH (thyroid-stimulating hormone) levels in people.&nbsp;</p>
<p>A noted educator, Dr. Surks led a collaborative project that culminated in a generic &ldquo;gold standard&rdquo; curriculum for endocrinology training programs that is used nationwide. He is author of <em>The Thyroid Book</em> and editor of the <em>Atlas of Clinical Endocrinology Volume I: Thyroid Diseases</em>. He has served on the editorial boards of several journals, including <em>Endocrinology</em> and the<em> Journal of Clinical Endocrinology &amp; Metabolism</em>, and currently is on the editorial board of <em>Thyroid</em>.&nbsp;</p>
<p>Dr. Surks is a member of the American Society for Clinical Investigation and the Association of American Physicians. He is a former president of the American Thyroid Association and the Association of Program Directors in Endocrinology, Diabetes and Metabolism. His awards include the American Thyroid Association&rsquo;s Distinguished Service Award and the Van Meter Award, and the Sidney H. Ingbar Distinguished Service Award of the Endocrine Society. He was also awarded a Mastership by the American College of Physicians in recognition of his contributions to research, education, and teaching.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol type="1">
<li>Cases, J.A., Wenig, B.M., Silver, C.E., Surks, M.I. Recurrent acute suppurative thyroiditis in an adult due to a pyriform-sinus (4th branchial pouch) fistula. J Clin Endocrinol &amp; Metab 85:953-956, 2000.</li>
<li>Cases, J.A., Surks, M.I. Changing role of scintigraphy in the evaluation of thyroid nodules; Seminars in Nuclear Medicine, Volume 30:81-87, 2000.</li>
<li>Surks, M.I., &lsquo;Hyperthyroidism&rsquo;; &lsquo;Hypothyroidism&rsquo;; &lsquo;Goiter&rsquo;; &lsquo;Iodine&rsquo;;;Thyroid Disorders&rsquo;; &lsquo;Thyroid Function Tests&rsquo;; in Encyclopedia of Public Health; Editor-in-Chief, Breslow, L., McMillan Reference USA, New York, 2002</li>
<li>Surks, M.I., Hyperthyroidism, Conn&rsquo;s Current Therapy, 2003 Eds Rakel and Bope; Elsevier Science (USA) 717-720.</li>
<li>Dubenko, M., Breining, W., Surks, M.I. &nbsp; Sclerosing lymphocytic lobulitis of the breast &nbsp; in a patient with Graves&rsquo; disease. &nbsp;2003 &nbsp;THYROID 13:309-311.</li>
<li>Rizza RA, Vigersky RA, Rodbard HW, Ladenson PW, Young WF Jr, Surks MI, Kahn R, Hogan PF. 2003. A model to determine workforce needs for endocrinologists in the United &nbsp;States until 2020. J Clin Endocrinol Metab 88: 1979-1987.</li>
<li>Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. &nbsp;Subclinical thyroid disease: Scientific Review and Guidelines for Diagnosis and Management. JAMA, 2004; 291: 228-238.&nbsp;</li>
<li>Col, NF, Surks MI. and Daniels GH: Subclinical thyroid disease: Clinical Applications. &nbsp; JAMA &nbsp;2004; 291: 239 &ndash; 243.</li>
<li>Senzel L, Surks MI, and Buettner C: Polyuria and abdominal pain in a &nbsp; young &nbsp; Jamaican woman. Laboratory Medicine, 2004; 35: 100 &ndash; 103.</li>
<li>Surks MI: Response: to &lsquo;Subclinical Thyroid Dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association and The Endocrine Society&rsquo; THYROID, 2005,15:32-33. &nbsp; &nbsp; &nbsp;&nbsp;</li>
<li>Surks MI: COMMENTARY: Subclinical Thyroid dysfunction: A joint statement on Management from the American Association of Clinical Endocrinologists, the American &nbsp;Thyroid &nbsp; &nbsp;Association, and The Endocrine society. J Clin Endocrinol Metab 2005, 90: 586-. 588</li>
<li>Surks, MI, Goswami G, Daniels GH: &nbsp;CONTROVERSY IN CLINICAL &nbsp;ENDOCRINOLOGY: The thyrotropin reference range should remain unchanged. J ClinEndcrinol Metab 2005; 5489 &ndash; 5496.</li>
<li>Surks, MI &nbsp;Hypothyroidism: New issues and controversies. The Endocrinologist. 2006.16: 203-208.</li>
<li>Meyerovitch J, Rotman-Pikiely P, Sherf M, Battat E, Levy Y, Surks MI: Serum &nbsp; &nbsp;thyrotropin (TSH) measurements in the community: 5-year follow-up in a large network of primary care physicians. Archives Internal Med &nbsp; 2007; 167: 1533 &ndash; 1538</li>
<li>Surks MI, Hollowell JG. &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol &amp; Metab &nbsp;2007; 92: 4575-4582</li>
<li>Surks MI, Hollowell JG: &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States Population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol and Metab 2007; 92: 4575-4582.</li>
<li>Surks, MI. 2008. Should the upper limit of the normal reference range for TSH be lowered? Nature Clinical Practice: Endocrinology and Metabolism 4: 370-371</li>
<li>Surks MI &nbsp;2008 Concise Review: TSH reference limits: Emerging concepts and implications for the prevalence of subclinical hypothyroidism. Clin Thyroidology 20:4-5.</li>
<li>Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I: 2009 Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab 94:1251-1254.</li>
<li>Atzmon G, Barzilai N, Surks MI, Gabriely I &nbsp;2009 &nbsp; Genetic Predisposition to Elevated &nbsp;Serum Thyrotropin is Associated with Exceptional Longevity. J Clin Endocrinol Metab &nbsp;94: 4768-4775</li>
<li>Surks MI &nbsp; &nbsp;2011 &nbsp; Milestones in Thyroid Research at Montefiore Medical Center: 1920 &ndash; 2011: History and Personal Reflections--in press</li>
<li>Cases, J.A., Wenig, B.M., Silver, C.E., Surks, M.I. Recurrent acute suppurative thyroiditis in an adult due to a pyriform-sinus (4th branchial pouch) fistula. J Clin Endocrinol &amp; Metab 85:953-956, 2000.</li>
<li>Cases, J.A., Surks, M.I. Changing role of scintigraphy in the evaluation of thyroid nodules; Seminars in Nuclear Medicine, Volume 30:81-87, 2000.</li>
<li>Surks, M.I., &lsquo;Hyperthyroidism&rsquo;; &lsquo;Hypothyroidism&rsquo;; &lsquo;Goiter&rsquo;; &lsquo;Iodine&rsquo;;;Thyroid Disorders&rsquo;; &lsquo;Thyroid Function Tests&rsquo;; in Encyclopedia of Public Health; Editor-in-Chief, Breslow, L., McMillan Reference USA, New York, 2002</li>
<li>Surks, M.I., Hyperthyroidism, Conn&rsquo;s Current Therapy, 2003 Eds Rakel and Bope; Elsevier Science (USA) 717-720.</li>
<li>Dubenko, M., Breining, W., Surks, M.I. &nbsp; Sclerosing lymphocytic lobulitis of the breast &nbsp; in a patient with Graves&rsquo; disease. &nbsp;2003 &nbsp;THYROID 13:309-311.</li>
<li>Rizza RA, Vigersky RA, Rodbard HW, Ladenson PW, Young WF Jr, Surks MI, Kahn R, Hogan PF. 2003. A model to determine workforce needs for endocrinologists in the United &nbsp;States until 2020. J Clin Endocrinol Metab 88: 1979-1987.</li>
<li>Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. &nbsp;Subclinical thyroid disease: Scientific Review and Guidelines for Diagnosis and Management. JAMA, 2004; 291: 228-238.&nbsp;</li>
<li>Col, NF, Surks MI. and Daniels GH: Subclinical thyroid disease: Clinical Applications. &nbsp; JAMA &nbsp;2004; 291: 239 &ndash; 243.</li>
<li>Senzel L, Surks MI, and Buettner C: Polyuria and abdominal pain in a &nbsp; young &nbsp; Jamaican woman. Laboratory Medicine, 2004; 35: 100 &ndash; 103.</li>
<li>Surks MI: Response: to &lsquo;Subclinical Thyroid Dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association and The Endocrine Society&rsquo; THYROID, 2005,15:32-33. &nbsp; &nbsp; &nbsp;&nbsp;</li>
<li>Surks MI: COMMENTARY: Subclinical Thyroid dysfunction: A joint statement on Management from the American Association of Clinical Endocrinologists, the American &nbsp;Thyroid &nbsp; &nbsp;Association, and The Endocrine society. J Clin Endocrinol Metab 2005, 90: 586-. 588</li>
<li>Surks, MI, Goswami G, Daniels GH: &nbsp;CONTROVERSY IN CLINICAL &nbsp;ENDOCRINOLOGY: The thyrotropin reference range should remain unchanged. J ClinEndcrinol Metab 2005; 5489 &ndash; 5496.</li>
<li>Surks, MI &nbsp;Hypothyroidism: New issues and controversies. The Endocrinologist. 2006.16: 203-208.</li>
<li>Meyerovitch J, Rotman-Pikiely P, Sherf M, Battat E, Levy Y, Surks MI: Serum &nbsp; &nbsp;thyrotropin (TSH) measurements in the community: 5-year follow-up in a large network of primary care physicians. Archives Internal Med &nbsp; 2007; 167: 1533 &ndash; 1538</li>
<li>Surks MI, Hollowell JG. &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol &amp; Metab &nbsp;2007; 92: 4575-4582</li>
<li>Surks MI, Hollowell JG: &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States Population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol and Metab 2007; 92: 4575-4582.</li>
<li>Surks, MI. 2008. Should the upper limit of the normal reference range for TSH be lowered? Nature Clinical Practice: Endocrinology and Metabolism 4: 370-371</li>
<li>Surks MI. 2008 Editorial: New evidence against lowering the thyrotropin reference limits. Clin Thyroidology 20: 8</li>
<li>Surks MI &nbsp;2008 Concise Review: TSH reference limits: Emerging concepts and implications for the prevalence of subclinical hypothyroidism. Clin Thyroidology 20:4-5.</li>
<li>Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I: 2009 Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab 94:1251-1254.</li>
<li>Atzmon G, Barzilai N, Surks MI, Gabriely I &nbsp;2009 &nbsp; Genetic Predisposition to Elevated &nbsp;Serum Thyrotropin is Associated with Exceptional Longevity. J Clin Endocrinol Metab &nbsp;94: 4768-4775</li>
<li>Surks MI &nbsp; &nbsp;2011 &nbsp; Milestones in Thyroid Research at Montefiore Medical Center: 1920 &ndash; 2011: History and Personal Reflections--in press</li>
</ol>

EMR ID

3515

Biography

<p>Martin I. Surks, MD, MACP, is an attending physician, Professor, Medicine, Pathology and Laboratory Medicine and Program Director Emeritus, Endocrines Clinic (1976-2018) at Montefiore Einstein. Dr. Surks&rsquo; clinical practice focuses on disorders of the thyroid gland and other disorders of general endocrinology such as diseases of the pituitary, parathyroid glands, gonads and adrenal glands, and metabolic bone disease.</p><p>After completing his Bachelor of Arts at Columbia College in 1956, Dr. Surks pursued his medical education at New York University - Bellevue College, earning his Doctor of Medicine in 1960. He began his postdoctoral training at Montefiore and completed it at Veterans Administration Hospital in 1963. Dr. Surks then returned to Montefiore to complete a postdoctoral research fellowship in arthritis and metabolic diseases in 1964.</p><p>The majority of Dr. Surks&rsquo; research focuses on thyroid physiology, pathophysiology and diseases. Most recently, he has studied subclinical thyroid diseases and the characterization of the reference range for serum TSH in human beings. He has shared his research in major peer-reviewed journals, and through editorials, abstracts, books and letters, having published more than 200 peer-reviewed papers and 2 books. He has also served on the editorial boards of several medical journals including <em>Endocrine Research, Thyroid</em> and the <em>Journal of Clinical Endocrinology and Metabolism</em>.</p><p>Dr. Surks is a Master of the American College of Physicians, a Diplomate of the National Board of Medical Examiners and a member of the American Association of Clinical Endocrinologists. He is past President of the American Thyroid Association and the Association of Program Directors of Endocrinology and Metabolism. Dr. Surks has earned many accolades throughout his career, including the Distinguished Service Award from the American Thyroid Association, the Sidney H. Ingbar Distinguished Service Award from the Endocrine Society and the Physician Recognition Award from the American Medical Association.</p>

Is Open Scheduling

On